Monte Rosa Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview

Monte Rosa Therapeutics

05/05/2025 13:46

Monte Rosa Therapeutics Inc GLUE.OQ GLUE.O is expected to show a rise in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

The Boston Massachusetts-based  company is expected to report a 1,239.3% increase in revenue to $14.25 million from $1.06 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Monte Rosa Therapeutics Inc is for a loss of 34 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Monte Rosa Therapeutics Inc is $16.50​, above​ its last closing price of $4.97. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.02
0.23
Beat
1,100
Sep. 30 2024
-0.46
-0.49
-0.29
Beat
40.4
Jun. 30 2024
-0.53
-0.54
-0.43
Beat
20.4​
Mar. 31 2024
-0.57
-0.57
-0.53
Beat
7.5
​​Dec. 31 2023
-0.30
-0.33
-0.58
Missed
-73.3
Sep. 30 2023
-0.72
-0.72
-0.70
Beat
3.3​
Jun. 30 2023
-0.69
-0.70
-0.71
Missed
-1.4
Mar. 31 2023
-0.68
-0.68
-0.65
Beat
4.3

This summary was machine generated May 5 at 12:46 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)